Compare Cassava Sciences Inc (FLNA) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lamb Weston Holdings Inc — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Lamb Weston Holdings Inc trades at $46.88 (market cap $6.29B). The key difference: Lamb Weston Holdings Inc is far larger — about 118.4× Cassava Sciences Inc's market cap, and Lamb Weston Holdings Inc pays a 3.34% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LW | |
|---|---|---|
Market Cap | $53.14M | $6.29B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $66.57 |
52-Week Low | $1.09 | $38.48 |
Enterprise Value | -$33.43M | $10.25B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Lamb Weston (LW) trades at $46.50, down 1.02% with a bullish technical outlook supported by moving averages. The company shows consistent earnings beats with Q2 2026 results pending, though net income declined to $357.2M in 2025. Valuation appears reasonable with P/E of 21.38 and P/S of 0.98. Recent news highlights strategic facility closures and upcoming Q4 earnings on July 24, 2026.
LW presents a mixed outlook with strong execution offset by margin pressure. The stock offers 6% upside to consensus target of $49.33, supported by activist involvement and cost initiatives. Key risks include legal challenges, ERP system issues, and volatile potato costs. Analyst sentiment is cautious with 35% buy ratings amid earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
